• Users Online: 417
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
CASE SERIES
Year : 2021  |  Volume : 23  |  Issue : 2  |  Page : 219-224

Risk factor profile of Mucormycosis in COVID 19 patients: A Case series


1 Classified specialist Medicine and Neurologist, Department of Medicine, Base Hospital, New Delhi, India
2 Classified specialist Medicine and Geriatrician, Department of Medicine, Base Hospital, New Delhi, India
3 Resident Medicine, Department of Medicine, Base Hospital, New Delhi, India
4 Resident Department of Pathology, Army Hospital, Research and Referral, New Delhi, India
5 Classified specialist Department of Radiology, Base Hospital, New Delhi, India
6 Clinical Biochemistry, Delhi, India

Correspondence Address:
Lt Col (Dr) Rahul Soni
Base Hospital, Delhi Cantt, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jmms.jmms_97_21

Rights and Permissions

Coronavirus disease-19 (COVID-19)-infected patients are at risk to develop severe opportunistic infections, especially fungal infections. The incidence of mucormycosis has increased in patients who are recovering from COVID-19 and now it has become an epidemic in India. In the background of the COVID-19 pandemic, we present a case series of seven patients with mucormycosis and their risk factor profile. Six of our patients had nonketotic poorly controlled glycemic status. All patients were mild or asymptomatic as far as COVID-19 clinical symptoms are concerned, but they had high inflammatory markers such as interleukin 6 (IL-6), ferritin, and D-dimer, which are commonly seen in a cytokine storm. Hyperglycemia and COVID-19 infection were consistent features in our patients. We found that COVID-19 patients with poor glycemic control and high inflammatory markers are at high risk for mucormycosis infection. However, the duration from the diagnosis of COVID-19 and the development of symptoms of mucormycosis was varied from 1 to 12 days (mean- 5.71). There was no correlation of the level of IL-6 or D-dimer with the early onset of mucormycosis. We also did not find any correlation of mucormycosis with other proposed risk factors such as oxygen therapy, steam inhalation, or prolonged steroid therapy, since four of our patients had never received steroids in any form and three had received only mild dosages of steroid. The sample size for statistical analysis was inadequate. However, a randomized clinical trial or larger observational study is needed to establish this observation.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed224    
    Printed9    
    Emailed0    
    PDF Downloaded23    
    Comments [Add]    

Recommend this journal